Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1492422/000156459020049423/apls-10q_20200930.htm
February 2024
January 2024
January 2024
December 2023
December 2023
November 2023
October 2023
August 2023
August 2023
July 2023
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
|
|
| ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
| |
(Address of Principal Executive Offices) |
(Zip Code) |
Registrant’s telephone number, including area code:
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1492422/000156459020049423/apls-10q_20200930.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Apellis Pharmaceuticals, Inc..
Apellis Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Rating
Learn More
The increase in interest income earned during the nine months ended September 30, 2020 was due to the interest earned on our cash and cash equivalents, which increased as a result of the completion of our follow-on offering of common stock in January 2020, the convertible note offerings in September 2019 and May 2020 and the payments to us under the SFJ agreement.
To date, we have financed our operations primarily through $772.1 million in net proceeds from public offerings of our common stock, including our initial public offering, or IPO, $535.8 million in net proceeds from the private offering of Convertible Notes, $112.6 million in proceeds from the private placement of shares of our convertible preferred stock prior to our IPO, $140.0 million under the SFJ agreement, $20.0 million in proceeds from borrowings under a term loan facility with Silicon Valley Bank, and 21 $7.0 million in proceeds from our issuance and sale of a promissory note.
The initial development plan sets forth the initial development activities to be conducted by each of us and Sobi, with our bearing all costs incurred in conducting the activities set forth in such initial development plan, as well as certain specified additional costs that are not included in the initial development plan that may be incurred by the parties in developing licensed products for paroxysmal nocturnal hemoglobinuria in the European Union and the United Kingdom.
The decrease in interest income earned during the three months ended September 30, 2020 was due to a decrease in the federal funds interest rate which resulted in a decrease in the interest earned on our cash, cash equivalents and marketable securities.
We are entitled to receive...Read more
We will also be entitled...Read more
Prior to our IPO, we...Read more
We will bear all costs...Read more
We expect to continue to...Read more
Net Cash Provided by Financing...Read more
Other Expense, Net Other expense,...Read more
We believe that our cash,...Read more
We believe that our cash,...Read more
We received net proceeds of...Read more
These increases will likely include...Read more
We presented data on five...Read more
Actual results or events could...Read more
We anticipate that our general...Read more
In addition, following certain events...Read more
In addition, following certain events...Read more
We would expect our research...Read more
We would expect our research...Read more
In January 2020, we announced...Read more
We received net proceeds of...Read more
Net cash used in operating...Read more
The increase was primarily related...Read more
If we raise funds through...Read more
32 We expect our expenses...Read more
The SFJ agreement was amended...Read more
The SFJ agreement was amended...Read more
Research and Development Expenses The...Read more
General and Administrative Expenses General...Read more
General and Administrative Expenses General...Read more
The increase in employee related...Read more
Pursuant to the agreement, SFJ...Read more
Pursuant to the agreement, SFJ...Read more
The net proceeds from the...Read more
The net proceeds from the...Read more
The net proceeds from the...Read more
On November 13, 2017, upon...Read more
On March 26, 2019, we...Read more
All statements, other than statements...Read more
Because of the numerous risks...Read more
Sobi has agreed to pay...Read more
The net proceeds from the...Read more
If the parties do not...Read more
We may redeem for cash...Read more
Interest Income Interest income was...Read more
The increase in general and...Read more
We have incurred significant annual...Read more
The remeasurement as of September...Read more
Net Cash Used in Investing...Read more
The capitalized amounts are expensed...Read more
We recently initiated a Phase...Read more
Net cash provided by financing...Read more
On March 11, 2019, we...Read more
On November 13, 2017, we...Read more
Although we expect that our...Read more
Loss from remeasurement of development...Read more
The increased employee related costs...Read more
The following critical accounting policies...Read more
Such payments will be proportionately...Read more
Additional data from the PEGASUS...Read more
We used $28.4 million of...Read more
We used $43.1 million of...Read more
We used $28.4 million of...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Apellis Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: APLS
CIK: 1492422
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-20-049423
Submitted to the SEC: Mon Nov 02 2020 6:32:07 AM EST
Accepted by the SEC: Mon Nov 02 2020
Period: Wednesday, September 30, 2020
Industry: Pharmaceutical Preparations